AIRLINK 75.20 Increased By ▲ 1.50 (2.04%)
BOP 4.89 Decreased By ▼ -0.01 (-0.2%)
CNERGY 4.40 Decreased By ▼ -0.12 (-2.65%)
DFML 43.04 Decreased By ▼ -1.84 (-4.1%)
DGKC 84.49 Decreased By ▼ -1.01 (-1.18%)
FCCL 21.35 Decreased By ▼ -0.05 (-0.23%)
FFBL 32.43 Decreased By ▼ -0.08 (-0.25%)
FFL 9.45 Decreased By ▼ -0.14 (-1.46%)
GGL 10.11 Decreased By ▼ -0.16 (-1.56%)
HASCOL 7.00 Decreased By ▼ -0.13 (-1.82%)
HBL 114.25 Decreased By ▼ -0.45 (-0.39%)
HUBC 139.18 Increased By ▲ 0.08 (0.06%)
HUMNL 12.08 Decreased By ▼ -0.34 (-2.74%)
KEL 4.92 Decreased By ▼ -0.11 (-2.19%)
KOSM 4.39 Decreased By ▼ -0.06 (-1.35%)
MLCF 37.10 Decreased By ▼ -0.50 (-1.33%)
OGDC 134.09 Decreased By ▼ -2.71 (-1.98%)
PAEL 25.15 Decreased By ▼ -0.24 (-0.95%)
PIBTL 6.63 Decreased By ▼ -0.06 (-0.9%)
PPL 119.05 Decreased By ▼ -1.95 (-1.61%)
PRL 26.12 Decreased By ▼ -0.47 (-1.77%)
PTC 13.85 Decreased By ▼ -0.25 (-1.77%)
SEARL 56.51 Decreased By ▼ -0.79 (-1.38%)
SNGP 67.00 Decreased By ▼ -1.00 (-1.47%)
SSGC 10.31 Decreased By ▼ -0.11 (-1.06%)
TELE 8.30 Decreased By ▼ -0.15 (-1.78%)
TPLP 10.97 Decreased By ▼ -0.01 (-0.09%)
TRG 62.60 Decreased By ▼ -0.74 (-1.17%)
UNITY 27.07 Increased By ▲ 0.02 (0.07%)
WTL 1.35 Decreased By ▼ -0.03 (-2.17%)
BR100 7,901 Decreased By -40.1 (-0.51%)
BR30 25,362 Decreased By -285.4 (-1.11%)
KSE100 75,257 Decreased By -260.3 (-0.34%)
KSE30 24,161 Decreased By -117.2 (-0.48%)
Business & Finance

Lilly asks FDA to not allow lone use of COVID-19 drug bamlanivimab

  • The request made to the US Food and Drug Administration is not due to any new safety issues, but in response to the new variants in the country that could be resistant to bamlanivimab when used alone, the drugmaker said in a statement.
  • Hospitals with bamlanivimab supply should now order etesevimab to pair with it, Lilly said.
Published April 16, 2021

Eli Lilly and Co said it had requested for cancellation of the US authorization granted to its COVID-19 antibody, bamlanivimab, which will now be used in combination with another to achieve greater efficacy against emerging virus variants.

The request made to the US Food and Drug Administration is not due to any new safety issues, but in response to the new variants in the country that could be resistant to bamlanivimab when used alone, the drugmaker said in a statement.

The US government stopped the distribution of the therapy last month.

Hospitals with bamlanivimab supply should now order etesevimab to pair with it, Lilly said.

Earlier this week, Lilly revised its pact with the US government to enable the supply of etesevimab to complement doses of bamlanivimab that the government had already purchased.

Etesevimab and bamlanivimab together neutralize more emerging COVID-19 variants in the US than bamlanivimab alone, including the rapidly growing B.1.427/B.1.429 California strain, Lilly said on Friday.

Lilly said it was not seeking cancellation of bamlanivimab's authorization in other countries, but its use was preferred in combination with etesevimab.

The drugmaker said it expects to make enough of the cocktail therapy along with partner Amgen to meet global supply needs.

Comments

Comments are closed.